Dogwood completes enrollment in Halneuron Phase 2b trial
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
12:51:42 PM UTC
SquawkNews
Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range -- Topline Data Expected in November 2026 -ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. NASDAQ:DWTX (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-op…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.